Network Point-of-Care Glucose Testing Market Size & Growth Forecast 2026–2035, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Network Point-of-Care Glucose Testing Market size was worth USD 1.43 Billion in 2025 and is expected to grow at a 4.5% CAGR between 2026 and 2035, exceeding USD 2.22 Billion by 2035. The industry revenue for 2026 is estimated at USD 1.48 billion.

• Base Year Value (2025): USD 1.43 Billion
• CAGR (2026-2035): 4.5%
• Forecast Year Value (2035): USD 2.22 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Network Point-of-Care Glucose Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 43.14% share due to advanced digital health infrastructure, widespread hospital adoption, and strong integration of glucose testing devices with electronic medical records.
  • Asia Pacific is growing at 5.13% CAGR driven by healthcare modernization, expanding hospital networks, and increasing adoption of connected point-of-care testing systems for faster clinical decision-making.

• Segment Momentum:

  • Accu-Chek Inform II leads the market because its established use in hospital and clinical workflows delivers reliable connectivity, standardized operation, and smooth integration into networked point-of-care testing environments.
  • CareSens Expert Plus is growing fastest as healthcare providers increasingly prioritize workflow flexibility, connected testing efficiency, and easy integration into digitally managed point-of-care testing processes.

• Market Expansion Drivers:

  • Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions.
  • Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes.
  • Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks.

• Leading Market Participants:

  Key companies in the network point-of-care glucose testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Nova Biomedical Corporation (United States), Ascensia Diabetes Care Holdings AG (Switzerland), Nipro Corporation (Japan), ACON Laboratories, Inc. (United States), Prodigy Diabetes Care, LLC (United States), Siemens Healthineers AG (Germany), LifeScan, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.43 Billion
  • Projected Market Size: USD 2.22 Billion by 2035
  • Growth Forecasts: 4.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Accu-Chek Inform II (Product)
  • Emerging Opportunity Segment: CareSens Expert Plus (Product)

Market Growth Drivers and Industry Trends

Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions

As diabetes case volumes rise, providers are under pressure to monitor larger patient populations without relying exclusively on central laboratory workflows, which pushes purchasing toward faster bedside and near-patient testing formats. In the network point-of-care glucose testing market, This transitions demand toward connected glucose meters that can deliver immediate readings in hospitals, outpatient clinics, long-term care settings, and emergency departments while automatically transmitting results into clinical systems. The practical effect is stronger instrument placement and recurring consumables use, as care teams prioritize rapid triage, insulin dosing support, and tighter glucose surveillance for a broader mix of routine and high-risk patients.

Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes

Remote patient monitoring is changing how diabetes is managed by making glucose data part of an ongoing clinical feedback loop rather than a series of isolated in-person measurements. For the network point-of-care glucose testing market, this supports market expansion by increasing the value of devices that can transmit accurate readings to clinicians, care coordinators, and digital platforms in near real time. Health systems and provider groups are more likely to favor networked testing solutions when those devices help identify excursions earlier, inform medication adjustments between visits, and reduce delays in intervention, especially for patients requiring closer supervision after discharge or in home-based care pathways.

Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks

As healthcare organizations invest in interoperable records, wireless connectivity, cloud-based data management, and device integration platforms, connected glucose testing becomes easier to deploy at scale rather than site by site. This is driving market development in the network point-of-care glucose testing market because buyers increasingly evaluate glucose meters not only on analytical performance but on how reliably they connect with electronic health records, middleware, and enterprise quality management systems. Integration reduces manual transcription, supports centralized oversight of operator compliance and device status, and gives multi-site providers a clearer operational case for standardizing on network-enabled point-of-care testing platforms.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions	2.00%	High	Asia Pacific, Middle East & Africa	High	Near Term
Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes	1.80%	High	North America, Europe	High	Mid Term
Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks	1.50%	Moderate	North America, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 43.14% share of the network point-of-care glucose testing market in 2025, supported by the region’s broad installed base of connected diagnostic systems across hospitals, clinics, and integrated care networks. Its leadership is strengthened by established digital health infrastructure, routine use of bedside glucose monitoring in acute care settings, and stronger interoperability between testing devices and electronic medical record platforms, which helps providers manage patient data more efficiently and sustain high testing volumes in day-to-day clinical practice.

Asia Pacific is projected to expand at a 5.13% CAGR over the forecast period in the network point-of-care glucose testing market, driven by the ongoing modernization of healthcare delivery and wider adoption of decentralized testing workflows. Growth is being propelled by increasing deployment of connected diagnostic equipment in hospitals and outpatient settings, where providers are placing greater emphasis on faster result access, more streamlined data transfer, and improved monitoring efficiency as healthcare systems scale capacity and digital connectivity.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Restrictive	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Distributed chronic care adoption

In the U.S., network-enabled point-of-care glucose testing is increasingly integrated into primary care and diabetes management programs, supporting decentralized monitoring across clinics and home-linked care networks. Providers in the U.S. emphasize connectivity with electronic health records and streamlined data sharing for continuous patient oversight.

Japan

Aging care monitoring systems

In Japan, demand is driven by aging population care models where networked glucose testing supports frequent monitoring in clinics and eldercare settings. Healthcare providers in Japan prioritize compact, reliable devices with seamless connectivity to centralized patient management platforms.

South Korea

Smart clinic connectivity

In South Korea, rapid digitization of healthcare services is supporting wider use of connected point-of-care glucose testing in clinics and community health centers. Providers in South Korea emphasize real-time data transfer and integration with digital health platforms for improved chronic disease management efficiency.

Germany

Digitized clinical integration

In Germany, adoption of network point-of-care glucose testing is shaped by structured healthcare systems prioritizing interoperability with hospital IT infrastructure. Clinical users in Germany focus on standardized data transmission and accuracy, particularly in diabetes management programs across outpatient and hospital-linked care pathways.

France

Structured diabetes pathways

In France, network point-of-care glucose testing is increasingly embedded in structured diabetes care pathways across primary and specialist settings. Healthcare facilities in France prioritize system compatibility and reliable data capture to support coordinated long-term patient monitoring.

Italy

Primary care modernization

In Italy, expansion of point-of-care glucose testing networks is linked to modernization of primary care services and chronic disease monitoring. Healthcare providers in Italy focus on cost-efficient, connected systems that improve workflow efficiency in outpatient diabetes management.

Segment Leadership and Growth Trends

  Product Segment Analysis: Accu-Chek Inform II (Largest Segment) vs CareSens Expert Plus (Fastest-Growing Segment)

Within the network point-of-care glucose testing market, Accu-Chek Inform II held the largest share in 2025, backed by its established presence in hospital and clinical testing workflows where connectivity, reliability, and standardized operation are central to routine glucose monitoring. its position is underpinned by the practical preference of care settings for systems already embedded in networked environments, since consistency in device performance and smoother integration with point-of-care management processes reduce operational disruption and support broad user adoption.

CareSens Expert Plus is emerging as the fastest-growing product in the network point-of-care glucose testing market as buyers increasingly weigh workflow flexibility and connected testing efficiency when evaluating newer device deployments. Its momentum is being influenced by demand for solutions that align with evolving point-of-care requirements in decentralized care environments, where ease of use and fit within digitally managed testing processes can accelerate uptake relative to more established alternatives.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus, BAROzen H Expert Plus	Accu-Chek Inform II	CareSens Expert Plus

Competitive Landscape and Market Positioning

Key companies in the network point-of-care glucose testing market:

1. Abbott Laboratories (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Nova Biomedical Corporation (United States)

4. Ascensia Diabetes Care Holdings AG (Switzerland)

5. Nipro Corporation (Japan)

6. ACON Laboratories Inc. (United States)

7. Prodigy Diabetes Care LLC (United States)

8. Siemens Healthineers AG (Germany)

9. LifeScan Inc. (United States)

The network point-of-care glucose testing market is evolving through digital integration that enhances real-time diagnostic connectivity and patient monitoring. Expansion into emerging healthcare settings is broadening accessibility of testing solutions. Research advancements are improving accuracy, speed, and usability of glucose testing systems.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	High	Dominated by Roche, Abbott, and Dexcom, with strong control over medical device markets.
M&A Activity / Consolidation Trend	Moderate	Acquisitions focus on integrating digital health and remote monitoring tech.
Degree of Product Differentiation	High	Advanced CGM systems, cloud connectivity, and AI analytics differentiate offerings.
Competitive Advantage Sustainability	Durable	Brand reputation, regulatory approvals, and data ecosystems sustain advantages.
Innovation Intensity	High	AI-driven analytics, wearable tech, and real-time data integration drive innovation.
Customer Loyalty / Stickiness	Strong	Patients and providers stick to trusted brands due to accuracy and integration needs.
Vertical Integration Level	Medium	Firms control device production and software, but rely on external cloud providers.

Industry Development/News

Company Name	Date	Key Development
Abbott Laboratories	Jun-24	Abbott Laboratories received FDA clearance for Libre Rio and Lingo over-the-counter glucose monitoring devices. Libre Rio targets type 2 diabetes patients not using insulin, while Lingo provides continuous glucose tracking with personalized metabolic insights, expanding access to consumer-focused glucose monitoring solutions.
Nova Biomedical	Mar-24	Nova Biomedical launched its next-generation StatStrip Glucose Hospital Meter System with FDA 510(k) clearance. The system introduces enhanced cybersecurity, RFID-enabled data entry, wireless charging, and ruggedized design to improve accuracy, connectivity, and operational reliability in critical care glucose testing environments.
Glooko	Jun-26	Glooko introduced an insulin pump settings EHR integration enabling device-agnostic visualization of basal rates and insulin-to-carbohydrate ratios directly within electronic health record systems. The solution enhances clinical decision-making by improving interoperability between diabetes devices and hospital data infrastructure.
Abbott	May-26	Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone biowearable sensors capable of continuous monitoring of both biomarkers from a single device. The approval expands Abbott’s multi-analyte monitoring capabilities in the European diabetes management market.
Glooko	May-26	Glooko obtained FDA 510(k) clearance for EndoTool IV Cloud, a cloud-based insulin dosing platform designed for hospital use. The solution supports automated insulin management workflows and strengthens digital therapeutics integration within inpatient diabetes care settings.
Trividia Health	Feb-26	Trividia Health issued a Class I recall for TRUE METRIX Blood Glucose Monitoring Systems due to an E-5 error code labeling issue. The recall impacts multiple regions and reflects regulatory action to ensure accuracy and safety in point-of-care glucose monitoring devices.
Ascensia Diabetes Care	Jan-26	Ascensia Diabetes Care transferred Eversense CGM commercialization rights to Senseonics, completing the U.S. transition in January 2026 with European transition expected by June 2026. The restructuring shifts commercial responsibilities for continuous glucose monitoring devices within the diabetes technology ecosystem.
Abbott Laboratories	Jun-24	Abbott Laboratories expanded its glucose monitoring portfolio with FDA-cleared consumer-oriented devices designed to extend continuous glucose monitoring beyond insulin-dependent patients. The development supports broader adoption of real-time metabolic health tracking in preventive and lifestyle healthcare segments.
Abbott Laboratories	Jun-24	Received FDA clearance for Libre Rio and Lingo over-the-counter glucose monitoring devices. Libre Rio is targeted at type 2 diabetes patients not using insulin, while Lingo provides continuous glucose tracking with personalized insights, expanding consumer-accessible glucose monitoring within the point-of-care ecosystem.
Nova Biomedical	Mar-24	Launched the StatStrip Glucose Hospital Meter System with FDA 510(k) clearance, featuring enhanced cybersecurity, wireless charging, RFID-enabled data entry, and ruggedized design to improve accuracy and secure glucose testing in critical care hospital environments.
Meta	Jun-25	Introduced generative AI video editing capabilities across Meta AI app and related platforms, enabling transformation of video content using AI prompts for style, setting, lighting, and narrative effects, supporting broader AI-driven content creation workflows.
Cartwheel	May-25	Launched a 3D animation AI tool suite that converts video, text, and motion libraries into production-ready 3D animations, enabling streamlined editing and integration into film, gaming, advertising, and digital content pipelines.
Google LLC	May-24	Introduced AI-powered advertising and search enhancements, including generative search experiences and tools enabling advertisers to create animated ads from still images with customizable branding elements for improved engagement and personalization.
Autodesk	May-24	Acquired Wonder Dynamics to integrate AI-enabled cloud-based 3D animation and VFX tools into its production ecosystem, strengthening end-to-end digital content creation capabilities across media and entertainment workflows.
Kartoon Studios, Inc.	Apr-24	Launched an AI-powered animation toolkit designed to improve production efficiency and content quality by integrating generative AI into animation workflows for enhanced creative output and streamlined studio operations.
Glooko	Jun-26	Introduced insulin pump settings EHR integration enabling visualization of device-agnostic insulin pump data within electronic health record systems, improving clinical decision-making through consolidated digital diabetes management data.
Abbott	May-26	Received CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone biowearable devices enabling simultaneous continuous monitoring of glucose and ketones from a single sensor platform.
Glooko	May-26	Obtained FDA 510(k) clearance for EndoTool IV Cloud, a cloud-based insulin dosing platform for hospital use, expanding digital therapeutics capabilities for inpatient glycemic management.
Trividia Health	Feb-26	Issued a Class I recall of TRUE METRIX Blood Glucose Monitoring Systems due to labeling-related E-5 error code issues, impacting multiple regional markets and requiring corrective quality and compliance actions.
Ascensia Diabetes Care	Jan-26	Entered agreement to transfer Eversense CGM commercialization rights to Senseonics, with U.S. transition completed in January 2026 and European transition expected by June 2026, restructuring its CGM commercialization footprint.